La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Firebrick Pharma Résultats passés
Passé contrôle des critères 0/6
Firebrick Pharma's earnings have been declining at an average annual rate of -33.8%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 64.7% per year.
Informations clés
-33.8%
Taux de croissance des bénéfices
1.7%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 31.2% |
| Taux de croissance des recettes | 64.7% |
| Rendement des fonds propres | -287.5% |
| Marge nette | -251.6% |
| Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14
We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30Ventilation des recettes et des dépenses
Comment Firebrick Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -5 | 2 | 4 |
| 30 Sep 23 | 1 | -6 | 2 | 4 |
| 30 Jun 23 | 0 | -7 | 2 | 4 |
| 31 Mar 23 | 1 | -6 | 2 | 4 |
| 31 Dec 22 | 1 | -5 | 2 | 4 |
| 30 Sep 22 | 1 | -5 | 2 | 3 |
| 30 Jun 22 | 1 | -4 | 2 | 2 |
| 31 Mar 22 | 1 | -3 | 2 | 2 |
| 31 Dec 21 | 0 | -3 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 2 | 1 |
| 30 Jun 20 | 1 | -1 | 0 | 2 |
Des revenus de qualité: FRE is currently unprofitable.
Augmentation de la marge bénéficiaire: FRE is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: FRE is unprofitable, and losses have increased over the past 5 years at a rate of 33.8% per year.
Accélération de la croissance: Unable to compare FRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: FRE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement des fonds propres
ROE élevé: FRE has a negative Return on Equity (-287.46%), as it is currently unprofitable.